• PL 56 (Viikinkaari 5)

    00014

    Finland

  • Viikinkaari 5, Biocenter 2

    00790 Helsinki

    Finland

1997 …2024

Forskningsoutput per år

Nätverk

Heikki Vuorela

Person: HU

Chinmaya Bhat

  • Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki

Extern person

Eero Mäki-Lohiluoma

  • University of Helsinki

Extern person

Jan Tytgat

  • Katholieke Universiteit Leuven, Belgium

Extern person

Steve Peigneur

  • Toxicology and Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven)

Extern person

Abedelmajeed Nasereddin

  • Hebrew Univ Jerusalem, Hebrew University of Jerusalem, Hadassah Med Sch, IMRIC, Dept Microbiol & Mol Genet

Extern person

Luis A. Pardo

  • Oncophysiology Group, Max-Planck-Institute of Experimental Medicine, Göttingen

Extern person

Dmitry Kopelyanskiy

  • Hebrew Univ Jerusalem, Hebrew University of Jerusalem, Hadassah Med Sch, IMRIC, Dept Microbiol & Mol Genet

Extern person

Lien Moreels

  • Toxicology and Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven)

Extern person

Olli Salin

  • Åbo Akademi University

Extern person

Roni T. Falk

  • NCI, National Institutes of Health (NIH) - USA, NIH National Cancer Institute (NCI), Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH

Extern person

Nives Hribernik

  • Division of Pharmaceutical Chemistry and Technology, Drug Research Program, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

Extern person

Charles L. Jaffe

  • Hebrew Univ Jerusalem, Hebrew University of Jerusalem, Hadassah Med Sch, IMRIC, Dept Microbiol & Mol Genet

Extern person

Jonathan M. Tyrrell

  • Cardiff University

Extern person

Laura M. Sanz

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Nuno Santarém

  • Instituto de Investigação e Inovação em Saúde da Universidade do Porto

Extern person

M. Belen Jimenez-Diaz

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Anna Rydzik

  • University of Oxford

Extern person

Louise Antonia Hendrickx

  • Toxicology and Pharmacology, Campus Gasthuisberg, University of Leuven

Extern person

Edgars Suna

  • Latvian Institute of Organic Synthesis

Extern person

Shifali Shishodia

  • University of Oxford

Extern person

Lázlo Béress

  • Hannover Medical School

Extern person

Gregers Wegener

  • Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University
  • Aarhus Univ, Aarhus University, Dept Clin Med, Translat Neuropsychiat Unit

Extern person

Lucija Peterlin Mašič

  • University of Ljubljana, The Faculty of Pharmacy
  • University of Ljubljana, The Faculty of Pharmacy

Extern person

Stuart P. McElroy

  • University of Dundee

Extern person

Sirpa Rasku

  • Department of Chemistry

Extern person

Michael McDonough

  • University of Oxford

Extern person

Iva Hopkins Navratilova

  • University of Dundee

Extern person

Angus Morrison

  • University of Dundee

Extern person

Eric Bacque

  • Evotec Infectious Diseases (Lyon)

Extern person

Anne-Sophie Depuydt

  • Toxicology and Pharmacology, Campus Gasthuisberg, University of Leuven

Extern person

Joanne Hewitt

  • University of Dundee

Extern person

Tobias Rüffer

  • Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie

Extern person

James Spencer

  • University of Bristol, UK

Extern person

Gareth Langley

  • University of Oxford

Extern person

Andrew D. Pannifer

  • University of Dundee

Extern person

Deuan C. Jones

  • University of Dundee

Extern person

Alistair Farley

  • University of Oxford

Extern person

Philip S. Jones

  • University of Dundee

Extern person

Elisabet Nielsen

  • Uppsala University

Extern person

Elena Sandoval-Izquierdo

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Solange Da Silva Pinto

  • University of Oxford

Extern person

Peter Brandt

  • Department of Medicinal Chemistry, Drug Design and Discovery, Uppsala University

Extern person

Farrah Zahed

  • Oncophysiology Group, Max-Planck-Institute of Experimental Medicine, Göttingen

Extern person

Juan Carlos Jimenez-Castellanos

  • Cardiff University, Cardiff, UK

Extern person

Maria S. Martinez-Martinez

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Lindsay Robinson

  • University of Dundee

Extern person

Michael Speake

  • University of Dundee

Extern person

Žan Toplak

  • University of Ljubljana, The Faculty of Pharmacy

Extern person

Mari Carmen Turrientes

  • Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Extern person

Pawel Donets

  • Latvian Institute of Organic Synthesis

Extern person

Tharindi Panduwawala

  • University of Oxford

Extern person

Tihomir Tomašič

  • University of Ljubljana, The Faculty of Pharmacy
  • University of Ljubljana, The Faculty of Pharmacy

Extern person

Andrei G. Baran

  • Latvian Institute of Organic Synthesis

Extern person

Mikko Heiskari

  • Univ Helsinki, University of Helsinki, Fac Pharm, Div Pharmaceut Chem & Technol

Extern person

Christopher J. Schofield

  • University of Oxford

Extern person

John Robinson

  • University of Dundee

Extern person

Edgars Liepins

  • Latvian Institute of Organic Synthesis

Extern person

Pia Vuorela

  • Åbo Akademi University

Extern person

Alastair J. Durie

  • University of St Andrews

Extern person

Pablo Castaneda-Casado

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Thomas Leissing

  • University of Oxford

Extern person

Heidi K. Müller

  • Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University

Extern person

Lluis Balla-Pages

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Heinrich Lang

  • Technische Universität Chemnitz, Fakultät für Naturwissenschaften, Institut für Chemie

Extern person

Rob Lesniak

  • University of Oxford

Extern person

Diego Olivieri

  • Department of Biomolecular Sciences, University Urbino Carlo Bo

Extern person

Simone Lucarini

  • Department of Biomolecular Sciences, University Urbino Carlo Bo

Extern person

Pawel Baranczewski

  • Uppsala University

Extern person

Felix Calderon

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Ali F. Aboklaish

  • Cardiff University, Cardiff, UK

Extern person

Anabela Cordeiro-da-Silva

  • Instituto de Investigação e Inovação em Saúde da Universidade do Porto

Extern person

Laura Espina

  • Cardiff University, Cardiff, UK

Extern person

M. Valeria D'Auria

  • Univ Naples Federico II, University of Naples Federico II, Dept Pharm

Extern person

Fiammetta Vitulano

  • Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki

Extern person

Maria Backlund

  • Uppsala University

Extern person

Irene Eteläinen

  • Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki

Extern person

Madeline E. Kavanagh

  • University of Oxford

Extern person

Marek Gniadkowski

  • National Medicines Institute

Extern person

Jürgen Brem

  • University of Oxford

Extern person

Victoria Barba

  • Division of Pharmaceutical Chemistry and Technology, Drug Research Program, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

Extern person

Margarita Puente-Felipe

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Manuela Vorácova

  • Division of Pharmaceutical Chemistry and Technology, Drug Research Program, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland

Extern person

Fernando Baquero

  • Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
  • CIBER Epidemiología y Salud Pública – CIBERESP

Extern person

Ernesto Lopes Pinheiro-Junior

  • Toxicology and Pharmacology, Campus Gasthuisberg, University of Leuven

Extern person

Janis Kuka

  • Latvian Institute of Organic Synthesis

Extern person

Jeffrey G. A. Walton

  • University of St Andrews

Extern person

Karina Calvopina

  • University of Oxford

Extern person

Emma Widlake

  • Cardiff University, Cardiff, UK

Extern person

Nicholas J. Westwood

  • University of St Andrews

Extern person

Rafael Canton

  • Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Extern person

Dmitrijs Lubriks

  • Latvian Institute of Organic Synthesis

Extern person

Gloria Buffi

  • Department of Biomolecular Sciences, University Urbino Carlo Bo

Extern person

Leticia Huertas-Valentin

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Matthew B. Avison

  • Cardiff University
  • Univ Bristol, University of Bristol, Sch Cellular & Mol Med

Extern person

Philip Hinchliffe

  • University of Bristol

Extern person

Daniel Krahn

  • University of Oxford

Extern person

Diogo T. Galan

  • Toxicology and Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven)

Extern person

Kirill Shubin

  • Latvian Institute of Organic Synthesis

Extern person

Alan H. Fairlamb

  • University of Dundee

Extern person

Luca Galluzzi

  • Department of Biomolecular Sciences, University Urbino Carlo Bo

Extern person

Sara Viera

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Malcolm G. P. Page

  • Jacobs Univ Bremen, Jacobs University

Extern person

Fredrik Björkling

  • University of Copenhagen

Extern person

Nicholas J. Westwood

  • Univ St Andrews, Sch Chem

Extern person

Timothy R. Walsh

  • Cardiff University, Cardiff, UK
  • Radcliffe Observatory Quarter

Extern person

Christian D. Muller

  • Univ Strasbourg, University of Strasbourg, Fac Pharm, Lab Innovat Therapeut, UMR CNRS 7200
  • Charite, Humboldt University of Berlin, Free University of Berlin, Charite Medical University of Berlin, Ctr Schlaganfallforsch
  • European Space Agcy, European Space Agency, ESTEC

Extern person

Laura Guijarro-Lopez

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Anna Karin Belfrage

  • Uppsala University

Extern person

Anders Eneroth

  • Uppsala University

Extern person

Hannah Goovaerts

  • Toxicology and Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven)

Extern person

Etienne Waelkens

  • Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, Leuven

Extern person

Nina Sacerdoti-Sierra

  • Hebrew Univ Jerusalem, Hebrew University of Jerusalem, Hadassah Med Sch, IMRIC, Dept Microbiol & Mol Genet

Extern person

Martins Priede

  • Latvian Institute of Organic Synthesis

Extern person

Edwin de Pauw

  • University of Liege

Extern person

Loic Quinton

  • University of Liege

Extern person

Benigno Crespo-Fernandez

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Gonzalo Gomez Campillos

  • University of Oxford

Extern person

Solveiga Grinberga

  • Latvian Institute of Organic Synthesis

Extern person

Laura de las Heras-Duena

  • GlaxoSmithKline, GlaxoSmithKline, Tres Cantos Med Dev Campus

Extern person

Aurora Diotallevi

  • Department of Biomolecular Sciences, University Urbino Carlo Bo

Extern person

Jon Ulf Hansen

  • Statens Serum Institut

Extern person

Juliane Schmidt (Adrian)

  • University of Oxford

Extern person

Marina Martjuga

  • Latvian Institute of Organic Synthesis

Extern person

Pauline A. Lang

  • University of Oxford, Department of Chemistry, Chemistry Research Laboratory and the Ineos Oxford Institute for Antimicrobial Research
  • Univ Oxford, University of Oxford, Oxford Parkinsons Dis Ctr

Extern person